Literature DB >> 3680992

Pentamidine pharmacokinetics in patients with AIDS with impaired renal function.

J E Conte1, R A Upton, E T Lin.   

Abstract

In patients with normal renal function, pentamidine elimination half-life and plasma clearance (mean +/- SD) were 6.22 +/- 1.17 hr and 411 +/- 55 liters/hr, respectively. With creatinine clearances from 35 to 145 ml/min, neither the elimination half-life (P = .47) nor the plasma clearance (P = .40) was correlated with renal function. Plasma concentrations in patients receiving dialysis ranged between 5.9 and 582 ng/ml and appeared not to be significantly affected by dialysis. The number of prior doses and the elimination half-life estimated from the terminal slope were correlated (r = .81, P = .025), and the results suggested that the current assay technology is still not sensitive enough to detect true elimination half-life. Trough plasma concentrations ranged between 4.3 and 67.5 ng/ml (28.4 +/- 26.6 ng/ml) in patients who had received prior doses of pentamidine, a result suggesting that drug accumulation occurs with multiple dosing. The data suggest that dosage adjustments are not necessary with creatinine clearances of greater than 35 ml/min. Because multiple dosing leads to increased trough concentrations and drug accumulation, lower dose regimens may still be efficacious, yet associated with reduced toxicity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3680992     DOI: 10.1093/infdis/156.6.885

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

Review 1.  Pentamidine. A risk-benefit analysis.

Authors:  B Wispelwey; R Pearson
Journal:  Drug Saf       Date:  1990 May-Jun       Impact factor: 5.606

2.  Pentamidine inhibits Coxiella burnetii growth and 23S rRNA intron splicing in vitro.

Authors:  Michael F Minnick; Linda D Hicks; James M Battisti; Rahul Raghavan
Journal:  Int J Antimicrob Agents       Date:  2010-10       Impact factor: 5.283

Review 3.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

5.  Concentrations of aerosolized pentamidine in bronchoalveolar lavage, systemic absorption, and excretion.

Authors:  J E Conte; J A Golden
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

6.  Pharmacokinetics and adverse reactions after a single dose of pentamidine in patients with Trypanosoma gambiense sleeping sickness.

Authors:  U Bronner; L L Gustafsson; F Doua; O Ericsson; T Miézan; M Rais; L Rombo
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

7.  Structure and inhibition of human diamine oxidase.

Authors:  Aaron P McGrath; Kimberly M Hilmer; Charles A Collyer; Eric M Shepard; Bradley O Elmore; Doreen E Brown; David M Dooley; J Mitchell Guss
Journal:  Biochemistry       Date:  2009-10-20       Impact factor: 3.162

8.  Acute, rapidly progressive renal failure with simultaneous use of amphotericin B and pentamidine.

Authors:  D Antoniskis; R A Larsen
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

Review 9.  Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Authors:  Anke E Kip; Jan H M Schellens; Jos H Beijnen; Thomas P C Dorlo
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

10.  Dosing Recommendations for Pediatric Patients With Renal Impairment.

Authors:  Amer Al-Khouja; Kyunghun Park; Daijha J C Anderson; Caitlyn Young; Jian Wang; Shiew Mei Huang; Mona Khurana; Gilbert J Burckart
Journal:  J Clin Pharmacol       Date:  2020-06-15       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.